Chimeric Therapeutics stopped its phase I/IIa study of CHM-2101, a cadherin-17-targeted autologous CAR T therapy for gastrointestinal cancers, after a second patient at the highest dose level experienced dose-limiting toxicities. The company said it will discontinue CHM-2101 in its current form. Chimeric plans to pivot to an early-stage in vivo CAR program targeting the same antigen. The shift reflects the pressure on cell-therapy developers to refine safety margins, particularly for solid-tumor constructs where on-target/off-tumor biology and cytokine-related toxicities can drive clinical holds. For investors and partners, the update signals a near-term reprioritization of pipeline assets rather than an incremental optimization within the existing ex vivo CAR T approach.